![](\"https:\/\/www.europesays.com\/britain\/wp-content\/uploads\/2026\/06\/a6263j000.jpg\"\/)
\u00a0<\/p>\nUNITED STATES<\/p>\n
SECURITIES AND EXCHANGE COMMISSION<\/p>\n
Washington, D.C. 20549<\/p>\n
\n\u00a0<\/p>\n
Form 6-K<\/p>\n
\n\u00a0<\/p>\n
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
\n15d-16<\/p>\n
UNDER THE SECURITIES EXCHANGE ACT OF 1934<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nFor the
\nmonth of June 2026<\/p>\n
\n\u00a0<\/p>\n
\nCommission
\nFile Number 001-15170<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
GSK plc<\/p>\n
\n(Translation
\nof registrant’s name into English)<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
79 New Oxford Street, London, WC1A 1DG<\/p>\n
\n(Address
\nof principal executive office)<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nIndicate
\nby check mark whether the registrant files or will file annual
\nreports under cover of Form 20-F or Form 40-F.<\/p>\n
\n\u00a0<\/p>\n
\nForm
\n20-F . . . .X. . . . Form 40-F . . . . . . . .<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
Issued: 24 June 2026, London UK<\/p>\n
\u00a0<\/p>\n
GSK announces commencement of tender offer to acquire Nuvalent,
\nInc.<\/p>\n
\u00a0\u00a0<\/p>\n
\n\u00a0<\/p>\n
GSK plc (LSE\/NYSE: GSK) today announced that Harmony Row
\nAcquisition Co. (“Purchaser”),
\na direct wholly-owned subsidiary of\u00a0\u200eGlaxoSmithKline
\nLLC (“GSK
\nLLC”), which is
\nan\u00a0\u200eindirect
\nwholly-owned subsidiary of GSK, has commenced a tender offer to
\npurchase all of the issued and outstanding shares of Class A Common
\nStock, par value $0.0001 per share (the “Class A
\nShares”), and Class B Common
\nStock, par value $0.0001 per share (the “Class B
\nShares” and, together with the
\nClass A Shares, the “Shares”)
\nof Nuvalent, Inc. (“Nuvalent”)
\n(NASDAQ: NUVL), for $124.00 per Share, net to the seller in cash,
\nwithout interest, subject to any applicable withholding taxes, and
\nupon\u00a0\u200ethe
\nterms and subject to the conditions set forth in the Offer to
\nPurchase, dated June 24, 2026, and the accompanying Letter of
\nTransmittal\u00a0\u200e\u200e(together,
\nand with other related materials,\u00a0as
\nthey may be amended or supplemented from time to time, the
\n“Offer”).<\/p>\n
\u00a0<\/p>\n
The Offer is being made pursuant to an Agreement and Plan of
\nMerger, dated as of June 9, 2026, by and among Nuvalent, GSK LLC,
\nPurchaser and solely for purposes of Section 9.14 therein, GSK. As
\nsoon as practicable following consummation of the Offer and subject
\nto the satisfaction or waiver of certain conditions, Purchaser will
\nmerge with and into Nuvalent (the “Merger”)
\nand the separate existence of Purchaser will cease and Nuvalent
\nwill continue as the surviving corporation and as a direct
\nwholly-owned subsidiary of GSK LLC. The Merger will be governed by
\nSection 251(h) of the General Corporation Law of the State of
\nDelaware, as amended (the “DGCL”),
\nwhich does not require a vote or action by written consent of
\nNuvalent’s stockholders.\u00a0\u200e<\/p>\n
\u00a0<\/p>\n
Nuvalent’s Board of Directors (the “Nuvalent
\nBoard”) has published a
\nSolicitation\/Recommendation Statement on Schedule 14D-9 (the
\n“Schedule
\n14D-9”) filed with the
\nSecurities and Exchange Commission (the “SEC”), which includes,
\namong other things, the recommendation of the Nuvalent Board that
\nNuvalent’s stockholders accept the Offer and tender their Shares to
\nPurchaser pursuant to the Offer.<\/p>\n
\u00a0<\/p>\n
The Offer and withdrawal rights will expire at one minute following
\n11:59 p.m.,\u00a0\u200eEastern
\nTime, on July 14, 2026, unless the Offer is\u00a0\u200eextended
\nor earlier terminated (such date, or any subsequent date to which
\nthe\u00a0\u200eexpiration
\nof the Offer is extended, the “Expiration
\nDate”).\u00a0\u200eAny
\nextension, delay, termination or amendment of the Offer will be
\nfollowed as promptly as practicable by a\u00a0\u200epublic
\nannouncement thereof, and such announcement, in the case of an
\nextension, will be made no later than 9:00\u00a0\u200ea.m.,
\nEastern Time, on the next business day after the previously
\nscheduled Expiration Date.\u00a0Purchaser is not providing for
\nguaranteed delivery procedures.<\/p>\n
\u00a0<\/p>\n
Purchaser’s obligation to pay for\u00a0\u200eShares
\nvalidly tendered (and not validly withdrawn) pursuant to the Offer
\nis subject to certain conditions, including, among others, (a) the
\nMinimum Tender Condition (as defined below); and (b) the expiration
\nor termination of the waiting period (and any extension thereof)
\nunder the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The
\n“Minimum Tender
\nCondition” means that there
\nshall have been validly tendered in the Offer and “received” by the
\n“depositary” (as such terms are defined in Section 251(h) of the
\nDGCL), and not validly withdrawn prior to the Expiration Date that
\nnumber of Class A Shares that, together with the number of Class A
\nShares, if any, then owned beneficially by GSK LLC and Purchaser
\n(together with their wholly-owned subsidiaries), represents at
\nleast a majority of the Class A Shares outstanding as of the
\nconsummation of the Offer.\u00a0\u200eThe
\nOffer is not subject to a financing condition.<\/p>\n
\u00a0<\/p>\n
The documentation relating to the Offer (including the Offer to
\nPurchase, the Letter of Transmittal and Schedule 14D-9) can be
\naccessed at the following link:\u00a0www.readourmaterials.com\/gsk2026\/.\u00a0The
\nOffer to Purchase, the related Letter of Transmittal and the
\nSchedule 14D-9 (which contains the recommendation of the Nuvalent
\nBoard and\u00a0\u200ethe
\nreasons therefor) contain important information. Nuvalent’s
\nstockholders should carefully read all documents
\nin\u00a0\u200etheir
\nentirety before any decision is made with respect to the
\nOffer.\u00a0\u200e<\/p>\n
\u00a0<\/p>\n
Questions or requests for assistance may be directed to Innisfree
\nM&A Incorporated (the “Information
\nAgent”) at\u00a0\u200ethe
\naddress and telephone numbers set forth below. Requests for copies
\nof the Offer to Purchase, the related Letter\u00a0\u200eof
\nTransmittal and other tender offer materials may be directed to the
\nInformation Agent or to brokers, dealers,\u00a0\u200ecommercial
\nbanks or trust companies. Such copies will be furnished promptly at
\nPurchaser’s expense.<\/p>\n
\u00a0<\/p>\n
INNISFREE M&A INCORPORATED<\/p>\n
500 Fifth Avenue, 21st Floor<\/p>\n
New York, NY 10110<\/p>\n
Shareholders May Call Toll Free:<\/p>\n
(877) 750-5838 (from the U.S. and Canada), or<\/p>\n
+1 (412) 232-3651 (from other countries)<\/p>\n
Banks and Brokers May Call Collect: (212) 750-5833<\/p>\n
\u00a0<\/p>\n
Additional information<\/p>\n
This press announcement is for informational purposes only and is
\nneither an offer to purchase nor a solicitation of an offer to sell
\nsecurities of Nuvalent, nor is it a substitute for any tender offer
\nmaterials that GSK, GSK LLC, Purchaser or Nuvalent have filed with
\nthe SEC. GSK, GSK LLC and Purchaser have filed a Tender Offer
\nStatement on Schedule TO with the SEC with respect to the Offer,
\nand Nuvalent has filed a Solicitation\/Recommendation Statement on
\nSchedule 14D-9 with the SEC with respect to the Offer. The Offer is
\nbeing made solely pursuant to the Offer to Purchase, and the
\nexhibits filed with respect thereto (including the Letter of
\nTransmittal), which contain the full terms and conditions of the
\nOffer. The Offer is not being made to (nor will tenders
\nbe\u00a0\u200eaccepted from or on behalf of) holders of Shares in
\nany jurisdiction in which the making of the Offer or
\nthe\u00a0\u200eacceptance thereof would not be in compliance with
\nthe securities, “blue sky” or other laws of such
\njurisdiction.\u00a0\u200eIn those jurisdictions where applicable
\nlaws or regulations require the Offer to be made by a licensed
\nbroker or\u00a0\u200edealer, the Offer shall be deemed to be made
\non behalf of Purchaser (as defined below) by one or more
\nregistered\u00a0\u200ebrokers or dealers licensed under the laws
\nof such jurisdiction to be designated by Purchaser. NUVALENT
\nSTOCKHOLDERS ARE URGED TO READ THE TENDER OFFER MATERIALS
\n(INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL
\nAND CERTAIN OTHER DOCUMENTS RELATING TO THE OFFER) AND THE
\nSOLICITATION\/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE
\nTHEY CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY
\nBEFORE ANY DECISION IS MADE WITH RESPECT TO THE OFFER. The Offer to
\nPurchase, the related Letter of Transmittal and certain other
\ndocuments relating to the Offer, as well as the
\nSolicitation\/Recommendation Statement on Schedule 14D-9, have been
\nsent to all record holders of Shares\u00a0\u200ewhose names appear
\non Nuvalent’s stockholder list. The Tender Offer Statement on
\nSchedule TO, the Solicitation\/Recommendation Statement on Schedule
\n14D-9, and other related documents are available for free at the
\nSEC’s website at\u00a0www.sec.gov.
\nAdditional copies may be obtained for free by contacting the
\nInformation Agent or to brokers, dealers,\u00a0\u200ecommercial
\nbanks or trust companies.<\/p>\n
\u00a0<\/p>\n
In addition to the Offer to Purchase, the related Letter of
\nTransmittal and certain other documents relating to the Offer, as
\nwell as the Solicitation\/Recommendation Statement on Schedule
\n14D-9, Nuvalent and GSK file or furnish, as applicable, annual,
\nquarterly and current reports and other information with the SEC.
\nNuvalent’s and GSK’s filings with the SEC are available to the
\npublic from commercial document-retrieval services and at the SEC’s
\nwebsite at\u00a0www.sec.gov<\/p>\n
\u00a0<\/p>\n
About\u00a0Nuvalent<\/p>\n
Nuvalent\u00a0(NASDAQ:
\nNUVL) is a clinical-stage biopharmaceutical company focused on
\ncreating precisely targeted therapies for patients with cancer,
\ndesigned to overcome the limitations of existing therapies for
\nclinically proven kinase targets. Leveraging deep expertise in
\nchemistry and structure-based drug design,\u00a0Nuvalent\u00a0develops
\ninnovative small molecules that have the potential to overcome
\nresistance, minimize adverse events, address brain metastases, and
\ndrive more durable responses.\u00a0Nuvalent\u00a0is
\nadvancing a robust pipeline with investigational candidates for
\nROS1-positive, ALK-positive, and HER2-altered non-small cell lung
\ncancer, and multiple discovery-stage research
\nprograms.<\/p>\n
\u00a0<\/p>\n
About GSK<\/p>\n
GSK is a global biopharma company with a purpose to unite science,
\ntechnology, and talent to get ahead of disease together. Find out
\nmore at\u00a0www.gsk.com.<\/p>\n
\u00a0<\/p>\n
GSK enquiries<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Media:<\/p>\n
Tim Foley<\/p>\n
+44 (0) 20 8047 5502<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
Sarah Clements<\/p>\n
+44 (0) 20 8047 5502<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
Kathleen Quinn<\/p>\n
+1 202 603 5003<\/p>\n
(Washington DC)<\/p>\n
\u00a0<\/p>\n
Sydney Dodson-Nease<\/p>\n
+1 215 370-4680<\/p>\n
(Philadelphia)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Investor Relations:<\/p>\n
Constantin Fest<\/p>\n
+44 (0) 7831 826525<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
James Dodwell<\/p>\n
+44 (0) 20 8047 2406<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
Mick Readey<\/p>\n
+44 (0) 7990 339653<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
Steph Mountifield<\/p>\n
+44 (0) 7796 707505<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
Sam Piper<\/p>\n
+44 (0) 7824 525779<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
Joanna Tuplin<\/p>\n
+44 (0) 7788 351650<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
Dan Smith<\/p>\n
+44 (0) 7823 523885<\/p>\n
(London)<\/p>\n
\u00a0<\/p>\n
Jeff McLaughlin<\/p>\n
+1 215 751 7002<\/p>\n
(Philadelphia)<\/p>\n
\u00a0<\/p>\n
Frannie DeFranco<\/p>\n
+1 215 751 3126<\/p>\n
(Philadelphia)<\/p>\n
\u00a0<\/p>\n
Cautionary statement regarding forward-looking
\nstatements<\/p>\n
GSK plc cautions investors that any forward-looking statements or
\nprojections made by GSK plc, including those made in this
\nannouncement, are subject to risks and uncertainties that may cause
\nactual results to differ materially from those projected. Such
\nfactors include, but are not limited to, those described in the
\n“Risk Factors” section in GSK plc’s Annual Report on Form 20-F for
\nthe year ended December 31, 2025, and GSK’s Q1 Results for 2026.
\nThis communication includes forward-looking statements related
\nto\u00a0Nuvalent,
\nand the acquisition of\u00a0Nuvalent\u00a0by
\nGSK plc that are subject to risks, uncertainties and other factors.
\nAll statements other than statements of historical fact are
\nstatements that could be deemed forward-looking statements,
\nincluding all statements regarding the intent, belief or current
\nexpectation of\u00a0Nuvalent\u00a0and
\nmembers of its senior management team and can typically be
\nidentified by words such as “believe,” “expect,” “estimate,”
\n“predict,” “target,” “potential,” “likely,” “continue,” “ongoing,”
\n“could,” “should,” “intend,” “may,” “might,” “plan,” “seek,”
\n“anticipate,” “project” and similar expressions, as well as
\nvariations or negatives of these words. Forward-looking statements
\ninclude, without limitation, statements regarding the merger,
\nsimilar transactions, prospective performance, future plans,
\nevents, expectations, performance, objectives and opportunities and
\nthe outlook for\u00a0Nuvalent’s
\nbusiness; the ability of\u00a0Nuvalent\u00a0to
\nsuccessfully commercialize its key products, including neladalkib
\nand zidesamtinib; the anticipated timing of clinical data and
\nregulatory filings or approvals relating to products; the
\npossibility of favorable or unfavorable results from clinical
\ntrials; the anticipated benefits of the acquisition; filings and
\napprovals relating to the transaction; the expected timing of the
\ncompletion of the transaction; the parties’ ability to complete the
\ntransaction; and the accuracy of any assumptions underlying any of
\nthe foregoing. Investors are cautioned that any such
\nforward-looking statements are not guarantees of future performance
\nand involve risks and uncertainties and are cautioned not to place
\nundue reliance on these forward-looking statements. Actual results
\nmay differ materially from those currently anticipated due to a
\nnumber of risks and uncertainties. Risks and uncertainties that
\ncould cause the actual results to differ from expectations
\ncontemplated by forward-looking statements include: uncertainties
\nas to the timing of the tender offer and completion of the merger;
\nthe possibility that various closing conditions for the transaction
\nmay not be satisfied or waived, including that\u00a0Nuvalent\u00a0stockholders
\nmay not tender into the offer a majority of the shares of Class A
\ncommon stock outstanding at the time of the expiration of the offer
\nor that required regulatory approvals may not be obtained or are
\nobtained subject to conditions that are not anticipated; the
\noccurrence of any event, change or other circumstance that could
\ngive rise to the termination of the merger agreement; the failure
\nto realize anticipated benefits of the proposed acquisition when
\nexpected or at all; potential adverse reactions or changes to
\nbusiness relationships resulting from the proposed acquisition,
\nincluding the effect of the announcement, pendency or consummation
\nof the acquisition on the ability of\u00a0Nuvalent\u00a0to
\nretain and hire key personnel or maintain key vendor, supplier or
\npartner relationships; risks that the proposed acquisition disrupts
\nthe current plans and operations of\u00a0Nuvalent;
\ntransaction costs; risks associated with potential litigation or
\nregulatory actions related to the transaction; and other risks and
\nuncertainties described from time to time in documents filed with
\nthe SEC by\u00a0Nuvalent,
\nincluding current reports on Form 8-K, quarterly reports on Form
\n10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9
\nfiled by\u00a0Nuvalent,
\nor in GSK plc’s Annual Report on Form 20-F for the year ended
\nDecember 31, 2025 filed with the SEC by GSK plc, as well as the
\nSchedule TO filed by GSK plc. All forward-looking statements are
\nbased on information currently available to GSK plc
\nand\u00a0Nuvalent,
\nand neither GSK plc nor\u00a0Nuvalent\u00a0assumes
\nany obligation to update any forward-looking
\nstatements.<\/p>\n
\u00a0<\/p>\n
GSK uses a number of adjusted measures, including Core results, to
\nreport the performance of its business, which are non-IFRS
\nmeasures. These measures are defined and reconciliations to the
\nnearest IFRS measure are available in GSK’s Q1 2026 Results and
\nGSK’s Annual Report on Form 20-F for FY 2025.<\/p>\n
\u00a0<\/p>\n
GSK provides earnings guidance to the investor community on the
\nbasis of Core results. This is in line with peer companies and
\nexpectations of the investor community, supporting easier
\ncomparison of the Group’s performance with its peers. GSK is not
\nable to give guidance for Total results as it cannot reliably
\nforecast certain material elements of the Total results,
\nparticularly the future fair value movements on contingent
\nconsideration and put options that can and have given rise to
\nsignificant adjustments driven by external factors such as currency
\nand other movements in capital markets.<\/p>\n
\u00a0<\/p>\n
All expectations, guidance and outlooks regarding future
\nperformance should be read together with the section “Guidance and
\noutlooks, assumptions and cautionary statements” on pages 44 and 45
\nof GSK’s Q1 2026 Results and the statements on page 328 of GSK’s
\nAnnual Report for FY 2025.<\/p>\n
\u00a0<\/p>\n
Registered in England & Wales:<\/p>\n
No. 3888792<\/p>\n
\u00a0<\/p>\n
Registered Office:<\/p>\n
79 New Oxford Street<\/p>\n
London<\/p>\n
WC1A 1DG<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
SIGNATURES<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nPursuant
\nto the requirements of the Securities Exchange Act of 1934, the
\nregistrant has duly caused this report to be signed on its behalf
\nby the undersigned, thereunto duly authorised.<\/p>\n
\u00a0<\/p>\n
GSK plc<\/p>\n
\u00a0<\/p>\n
\n(Registrant)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nDate:\u00a0June
\n24, 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nBy:\/s\/\u00a0VICTORIA
\nWHYTE<\/p>\n
\n————————–<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nVictoria\u00a0Whyte<\/p>\n
\u00a0<\/p>\n
\nAuthorised
\nSignatory for and on<\/p>\n
\u00a0<\/p>\n
\nbehalf
\nof GSK plc<\/p>\n","protected":false},"excerpt":{"rendered":"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 Form 6-K \u00a0 REPORT OF FOREIGN PRIVATE ISSUER…\n","protected":false},"author":2,"featured_media":67042,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20784],"tags":[32221,32872,32869,31732,20785,32871,16905,28912,32870,28952],"class_list":["post-71723","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gsk","tag-124-per-share","tag-biopharma-ma","tag-cash-acquisition","tag-form-6-k","tag-gsk","tag-hart-scott-rodino","tag-merger","tag-nuvalent","tag-section-251h","tag-tender-offer"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/116822684719787317","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/71723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=71723"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/71723\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/67042"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=71723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=71723"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=71723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}